NewsEvents

Your Yourlocation: Home > Effect of tiotropium bromide(136310-93-5) combined with high-dose sulindetil in the treatment of severe bronchial asthma complicated with chronic obstructive pulmonary disease

To evaluate the clinical value of tiotropium bromide(136310-93-5) combined with high-dose sulindetil in the treatment of severe bronchial asthma with chronic obstructive pulmonary disease (COPD). Methods: Sixty-seven patients with severe bronchial asthma complicated with COPD were enrolled in our hospital from April 2014 to April 2015. The patients were divided into two groups. 33 patients treated with tiotropium bromide were treated with tiotropium bromide. The other 34 patients treated with sulinda were treated by the study group, comparing the therapeutic effects of the two groups. Results: The FEV1, the peak expiratory flow rate (PEF) and the 1 second forced expiratory volume (FEV1%) were better than those in the control group (P <0.05). Conclusion: Tiotropium combined with high-dose sulindipine in the treatment of severe bronchial asthma with COPD is effective and can be used.

To investigate the clinical effect of tiotropium bromide(136310-93-5) inhalation agent combined with budesonide dermotam powder, inhalation combined with noninvasive ventilation in the treatment of chronic obstructive pulmonary disease (COPD) with carbon dioxide (CO2) retention. Methods: From January 2014 to 2016 in June, 78 patients with COPD with CO2 retention were divided into two groups: routine group (n = 38) and combined group (n = 40) according to the method of treatment. Routine group was given routine symptomatic treatment, the patients were treated with tiotropium bromide inhaler and combination of budesonide dermotam powder inhalation and noninvasive ventilation for 12 weeks. The changes of lung function, changes in blood gas and adverse events were compared between the two groups after 12 weeks of treatment. FEV1, forced vital capacity (FVC) and FEV1 /FVC were significantly higher in the combined group than those in the conventional group (P <0.05). After treatment, PaO2 was significantly lower in the combined group than in the conventional group, and the arterial oxygen pressure (PaO2) was significantly higher than that in the conventional group (P <0.05). Conclusion: Tiotropium bromide(136310-93-5) powder inhalation agent combined with budesonide dermotoril powder inhalation agent. Noninvasive ventilation therapy for COPD with CO2 retention in patients with clinical efficacy and safety.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved